These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7258379)

  • 1. The effect of pimozide on CSF norepinephrine in schizophrenia.
    Sternberg DE; van Kammen DP; Lake CR; Ballenger JC; Marder SR; Bunney WE
    Am J Psychiatry; 1981 Aug; 138(8):1045-50. PubMed ID: 7258379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noradrenaline levels in cerebrospinal fluid of drug-free and pimozide-treated schizophrenic patients.
    Maj M; Arena F; Volpe M; Kemali D
    Acta Neurol (Napoli); 1983 Dec; 5(6):461-7. PubMed ID: 6670602
    [No Abstract]   [Full Text] [Related]  

  • 3. CSF levels of gamma-aminobutyric acid in schizophrenia. Low values in recently ill patients.
    van Kammen DP; Sternberg DE; Hare TA; Waters RN; Bunney WE
    Arch Gen Psychiatry; 1982 Jan; 39(1):91-7. PubMed ID: 7055411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma norepinephrine in chronic schizophrenia.
    Breier A; Wolkowitz OM; Roy A; Potter WZ; Pickar D
    Am J Psychiatry; 1990 Nov; 147(11):1467-70. PubMed ID: 2221157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF monoamine metabolites in depression and schizophrenia.
    Berger PA; Faull KF; Kilkowski J; Anderson PJ; Kraemer H; Davis KL; Barchas JD
    Am J Psychiatry; 1980 Feb; 137(2):174-80. PubMed ID: 7352572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Norepinephrine turnover under neuroleptic treatment of schizophrenic syndromes (author's transl)].
    Eben E; Ackenheil M; Rüther E
    Arzneimittelforschung; 1978; 28(9):1498. PubMed ID: 38809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment.
    van Kammen DP; Docherty JP; Bunney WE
    Biol Psychiatry; 1982 Feb; 17(2):233-42. PubMed ID: 7074181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations.
    Maas JW; Bowden CL; Miller AL; Javors MA; Funderburg LG; Berman N; Weintraub ST
    Schizophr Bull; 1997; 23(1):147-54. PubMed ID: 9050120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients.
    Gattaz WF; Riederer P; Reynolds GP; Gattaz D; Beckmann H
    Psychiatry Res; 1983 Apr; 8(4):243-50. PubMed ID: 6576391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histochemical changes in the blood cells of schizophrenic patients under pimozide treatment.
    Stefanis CN; Issidorides MR
    Biol Psychiatry; 1976 Feb; 11(1):53-68. PubMed ID: 769850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between estimated premorbid adjustment and CSF homovanillic acid and 5-hydroxyindoleacetic acid levels.
    Leckman JF; Bowers MB; Sturges JS
    Am J Psychiatry; 1981 Apr; 138(4):472-7. PubMed ID: 6163366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between CSF noradrenaline levels, C-EEG indicators of activation and psychosis ratings in drug-free schizophrenic patients.
    Kemali D; Maj M; Iorio G; Marciano F; Nolfe G; Galderisi S; Salvati A
    Acta Psychiatr Scand; 1985 Jan; 71(1):19-24. PubMed ID: 3969838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Further exploration of the dopamine hypothesis of schizophrenia.
    van Kammen DP; Docherty JP; Marder SR; Rayner JN; Bunney WE
    Arch Gen Psychiatry; 1982 Mar; 39(3):275-81. PubMed ID: 6802100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.
    Garver DL; Bissette G; Yao JK; Nemeroff CB
    Am J Psychiatry; 1991 Apr; 148(4):484-8. PubMed ID: 2006695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent?
    van Kammen DP; Hommer DW; Malas KL
    Neuropsychobiology; 1987; 18(3):113-7. PubMed ID: 3453426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine response.
    van Kammen DP; Docherty JP; Marder SR; Schulz SC; Dalton L; Bunney WE
    Arch Gen Psychiatry; 1982 Mar; 39(3):261-6. PubMed ID: 7065839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decrease of CSF dopamine, its metabolites and noradrenalin after withdrawal of chronic neuroleptic treatment in schizophrenic patients.
    Bagdy G; Perényi A; Arató M; Rotstein E
    Psychiatry Res; 1984 Jun; 12(2):177-8. PubMed ID: 6147870
    [No Abstract]   [Full Text] [Related]  

  • 18. Pimozide treatment of the negative schizophrenic syndrome: an open trial.
    Feinberg SS; Kay SR; Elijovich LR; Fiszbein A; Opler LA
    J Clin Psychiatry; 1988 Jun; 49(6):235-8. PubMed ID: 3288615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients.
    van Kammen DP; Docherty JP; Marder SR; Schulz SC; Bunney WE
    Arch Gen Psychiatry; 1980 Mar; 37(3):287-90. PubMed ID: 6102456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study.
    Haas S; Beckmann H
    Pharmacopsychiatria; 1982 Mar; 15(2):70-4. PubMed ID: 7043498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.